Life Sciences
XORTX Maps Q4 FDA IND Filing as XRx-026 Gout Program Moves Toward Its Next Regulatory Step
XORTX plans a fourth-quarter IND submission for XRx-026 and has outlined the clinical, manufacturing and regulatory work intended to support a future U.S. marketing application.
Read full report →